The drug comes in extended release tablets, which strive to manage the neuropathic pain associated with diabetic peripheral neuropathy in adults.
The medication also aims to help adults with severe chronic pain resulting from extended use of an opioid analgesic.
Clinical studies found NUCYNTA use resulted in a one-point reduction in pain intensity during a three week treatment period and substantial pain improvement after 12 weeks.
More Articles on Anesthesia:
Face, Hand Transplant Initial Anesthesia Guidelines Released
Dr. Kenneth Sauve Joins Rutherford Regional Medical Center as Anesthesiologist
Sleep Apnea Diagnostic and Portable Anesthesia Systems Deemed Fastest Growing Markets
